Navigation Links
Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
Date:5/8/2008

as given for only 24 percent of FLECTOR(R) Patch patients versus 34.4 percent of placebo patch patients (p<0.01).

Of the 418 patients randomized in the study, 49.3 percent were men and 99.5 percent were white. The mean age of the study participants was 38.9 years. The most common injuries reported were contusions (42.6 percent), strains (31.1 percent), and sprains (24.4 percent); the most common injury sites were ankle, shoulder, knee and foot (67.3 percent). Efficacy was evaluated in 384 (91.9 percent) patients (greater than or equal to one post- baseline pain assessment). Adverse events were similar between FLECTOR(R) Patch and placebo patch; the most common were application-site conditions, generally of mild severity (FLECTOR(R) Patch 7.9 percent, placebo patch 5.8 percent). The study was supported by a grant from Alpharma Pharmaceuticals LLC.

Comparison of Plasma Pharmacokinetics of FLECTOR(R) Patch and Oral Voltaren(R) in Healthy Volunteers (Abstract #8383/Poster #279)(3)

In order to compare the bioavailability of two formulations containing diclofenac, FLECTOR(R) Patch and Voltaren(R), a single-center, open-label, crossover study was conducted in 24 healthy volunteers. All study subjects received one FLECTOR(R) Patch every 12 hours for four consecutive days; 12 study subjects received a single 50-mg oral dose of Voltaren(R) in a two-way crossover fashion. Blood was collected at selected times post-dose to determine diclofenac plasma levels.

Results indicated that the systemic exposure to diclofenac with topical FLECTOR(R) Patch at a steady state (every 12 hours for four days) was approximately 1 percent of a single dose of Voltaren(R) (50-mg oral).

The study included an equal number of males and females, all Caucasian, with a mean age of 24.1 years. Subjects were required to have no skin disorders or abnormalities at the patch application site. Mean Cmax for FLECTOR(R) Patch (steady state) was 1.7 plus or minus 0.9ng/mL versu
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 BioSpecifics Technologies Corp. (Nasdaq: ... in class collagenase-based products, today announced top-line efficacy ... trial of XIAFLEX(TM) for the treatment of Peyronie,s ... of inelastic collagen on the shaft of the ... sexual intercourse difficult or impossible in advanced cases. ...
(Date:12/16/2009)... -- MAQUET Cardiovascular LLC, a leading provider ... has signed a three-year single source provider ... contracting company, for MAQUET,s market-leading VASOVIEW Endoscopic ... assist healthcare providers in obtaining veins for ... small incisions. This allows for faster healing, ...
(Date:12/16/2009)... -- The Boards of Silence Therapeutics plc (AIM: ... the merger of their businesses to form a ... interference). The enlarged company, to be called ... and delivery technologies, a broad internal and partnered ... property. ,, The Directors believe the merger ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6CuraGen Updates CR011 vcMMAE Data at ASCO 4512 1CuraGen Updates CR011 vcMMAE Data at ASCO 4512 2CuraGen Updates CR011 vcMMAE Data at ASCO 4512 3CuraGen Updates CR011 vcMMAE Data at ASCO 4512 4CuraGen Updates CR011 vcMMAE Data at ASCO 4512 5CuraGen Updates CR011 vcMMAE Data at ASCO 4512 6CuraGen Updates CR011 vcMMAE Data at ASCO 4512 7Abbott 26 BioGenex Extend the Technology Co development and Distribution Agreement for Marketing the Xmatrx 28R 29 Advanced Staining Platform for the 12406 1Abbott 26 BioGenex Extend the Technology Co development and Distribution Agreement for Marketing the Xmatrx 28R 29 Advanced Staining Platform for the 12406 2The Killing of George Tiller 3A Video 26quot 3BThine Eyes 26quot 3B Shows True Face of Pro life Movement in the Face of 26apos 3BTerrorist 26apos 3 47577 1The Killing of George Tiller 3A Video 26quot 3BThine Eyes 26quot 3B Shows True Face of Pro life Movement in the Face of 26apos 3BTerrorist 26apos 3 47577 2
... alfa-2b) dosed every two weeks met the primary ... peginterferon alfa-2a dosed weekly in patients with genotype ... 900-mcg Albuferon had comparable rates of serious and/or ... of global marketing applications planned in fall 2009 ...
... 6 The American Medical Association (AMA) Foundation announced today the 28 ... the program provides $2,500 grants to medical students, physician residents and fellows ... award winners are conducting research in the following four categories: , ... Cardiovascular/pulmonary diseases , HIV/AIDS , ...
Other Medicine Technology:Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
(Date:12/16/2009)... Dec. 16 Shoppers like knowing if ... or Argentina. But grocers have found it burdensome ... (COOL) laws requiring them to provide the information ... at easyCOOLnow.com for easily making grocery ... include provisions that require retailers of unprocessed fruits, ...
(Date:12/16/2009)... MassMutual,s Retirement Services Division has announced plans to ... Q2 2010. The new platform will include a ... materials in a variety of themes. Plan sponsors ... menu of creative options to support the theme ... new RetireSmart participant engagement platform will be phased ...
(Date:12/16/2009)... School of Medicine,s (BUSM) Pulmonary Center has received ... Heart, Lung, and Blood Institute to derive stem ... disease. , Darrell Kotton, MD, associate professor ... PhD, assistant professor of medicine, are the principal ... and Mostoslavsky lead a multicenter investigative team of ...
(Date:12/16/2009)... agency, is honored to announce that Chris Wepfer and Jackie ... Year in Healthcare Traveler magazine’s 2009 Recruiters of the Year ... received such honors and the first for Jackie. , ... ... Solutions, a national healthcare staffing agency, is honored to announce ...
(Date:12/16/2009)... Medizone International, Inc. (OTC Bulletin Board: MZEI) ... the Board of Medizone New Zealand Ltd., a ... a 50% interest, agreed on December 14, 2009 ... Medizone International all global marketing rights of the ... G. Marshall said, "Time has eroded the relevance ...
Breaking Medicine News(10 mins):Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2
... Calif., May 12 Medical Care Corporation (MCC), ... technology, announced today that physicians now have a ... Screen, which enables them to accurately separate normal ... of memory loss associated with an underlying medical ...
... Call to Action demonstrates commitment to combating a leading ... and WaterAid America released two new reports today that ... are not responding to clear evidence on child mortality ... Diarrheal disease, a leading killer of children under age ...
... the skin , , TUESDAY, May 12 (HealthDay News) -- Any ... eased chronic lower back pain in a group of adult ... Cherkin, lead author of a report published in the May ... "Acupuncture is an effective treatment for chronic back pain. People ...
... Week 2009 -CAMBRIDGE, Mass. and NEW YORK, May 12, ... (NYSE: FRX ) today announced they will ... studies for linaclotide, a first-in-class investigational compound for the ... chronic constipation (CC), during the 2009 Digestive Disease Week ...
... 12 Last month The National Alliance of Advocates for ... patients seeking treatment for painkiller or heroin addiction compared to ... track for an astounding 200% gain. Dr. Michael Stein, author ... Oprah Magazine and The New York Times , tells ...
... MOUNTAIN VIEW, Calif., May 12 Based on ... market, Frost & Sullivan recognizes Sypris Test & ... & Sullivan Customer Service Leadership Award. This ... constant innovations, and strategic partnerships that have given ...
Other Medicine News:Health News:Medical Care Corporation Enables Early Detection of Memory Loss Due to Alzheimer's Disease 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 3Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 4Health News:Acupuncture, Real or Fake, Eases Back Pain 2Health News:Acupuncture, Real or Fake, Eases Back Pain 3Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 2Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 3Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 4Health News:Economy Impacts People Seeking Treatment for Addiction - 80% Increase Over Last Year 2Health News:Economy Impacts People Seeking Treatment for Addiction - 80% Increase Over Last Year 3Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 2Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 3Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 4
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
Portable shields for your safety and convenience....
Medicine Products: